FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336704086> ?p ?o ?g. }

• W2336704086 endingPage "66" @default.
• W2336704086 startingPage "655" @default.
• W2336704086 abstract "The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated. Analysis of a panel of 15 human P-450 cDNAs expressed in human lymphoblasts and/or baculovirus-infected insect cells (Supersomes) demonstrated that CYPs 2A6, 2B6, 3A4, 3A5, and three CYP2C enzymes (2C9, 2C18, 2C19) exhibited significant oxazaphosphorine 4-hydroxylase activity, with 2B6 and 3A4 displaying the highest activity toward CPA and IFA, respectively. CYP2B6 metabolized CPA at a approximately 16-fold higher in vitro intrinsic clearance (apparent Vmax/Km) than IFA, whereas 3A4 demonstrated approximately 2-fold higher Vmax/Km toward IFA. A relative substrate-activity factor (RSF)-based method was developed to calculate the contributions of individual P-450s to total human liver microsomal metabolism based on cDNA-expressed P-450 activity data and measurements of the liver microsomal activity of each P-450 form. Using this method, excellent correlations were obtained when comparing measured versus predicted (calculated) microsomal 4-hydroxylase activities for both CPA (r = 0. 96, p <.001) and IFA (r = 0.90, p <.001) in a panel of 17 livers. The RSF method identified CYP2B6 as a major CPA 4-hydroxylase and CYP3A4 as the dominant IFA 4-hydroxylase in the majority of livers, with CYPs 2C9 and 2A6 making more minor contributions. These predicted P-450 enzyme contributions were verified using an inhibitory monoclonal antibody for 2B6 and the P-450 form-specific chemical inhibitors troleandomycin for 3A4 and sulfaphenazole for 2C9, thus validating the RSF approach. Finally, Western blot analysis using anti-2B6 monoclonal antibody demonstrated the presence of 2B6 protein at a readily detectable level in all but one of 17 livers. These data further establish the significance of human liver CYP2B6 for the activation of the clinically important cancer chemotherapeutic prodrug CPA." @default.
• W2336704086 created "2016-06-24" @default.
• W2336704086 creator A5057744684 @default.
• W2336704086 creator A5075409072 @default.
• W2336704086 creator A5084967276 @default.
• W2336704086 creator A5088332392 @default.
• W2336704086 date "1999-06-01" @default.
• W2336704086 modified "2023-09-23" @default.
• W2336704086 title "Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles." @default.
• W2336704086 cites W1497370031 @default.
• W2336704086 cites W1504223539 @default.
• W2336704086 cites W1526269646 @default.
• W2336704086 cites W1563609352 @default.
• W2336704086 cites W1568250830 @default.
• W2336704086 cites W1578780451 @default.
• W2336704086 cites W1587549092 @default.
• W2336704086 cites W1589747510 @default.
• W2336704086 cites W1765706822 @default.
• W2336704086 cites W1892498374 @default.
• W2336704086 cites W1956507658 @default.
• W2336704086 cites W1971023121 @default.
• W2336704086 cites W1977244553 @default.
• W2336704086 cites W1987696276 @default.
• W2336704086 cites W1994029494 @default.
• W2336704086 cites W1999144842 @default.
• W2336704086 cites W2000081972 @default.
• W2336704086 cites W2008984280 @default.
• W2336704086 cites W2027151281 @default.
• W2336704086 cites W2027376002 @default.
• W2336704086 cites W2028603080 @default.
• W2336704086 cites W2029327304 @default.
• W2336704086 cites W2038160619 @default.
• W2336704086 cites W2042525065 @default.
• W2336704086 cites W2046563782 @default.
• W2336704086 cites W2051175552 @default.
• W2336704086 cites W2055531366 @default.
• W2336704086 cites W2058385006 @default.
• W2336704086 cites W2058400757 @default.
• W2336704086 cites W2066600629 @default.
• W2336704086 cites W2071498692 @default.
• W2336704086 cites W2077379882 @default.
• W2336704086 cites W2086187998 @default.
• W2336704086 cites W2086694311 @default.
• W2336704086 cites W2089921597 @default.
• W2336704086 cites W2092615420 @default.
• W2336704086 cites W2097725309 @default.
• W2336704086 cites W2112381649 @default.
• W2336704086 cites W2113576650 @default.
• W2336704086 cites W2124871526 @default.
• W2336704086 cites W2131614625 @default.
• W2336704086 cites W2140690834 @default.
• W2336704086 cites W2148849061 @default.
• W2336704086 cites W2155268095 @default.
• W2336704086 cites W2267140038 @default.
• W2336704086 cites W2331424524 @default.
• W2336704086 cites W2527229227 @default.
• W2336704086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10348794" @default.
• W2336704086 hasPublicationYear "1999" @default.
• W2336704086 type Work @default.
• W2336704086 sameAs 2336704086 @default.
• W2336704086 citedByCount "102" @default.
• W2336704086 countsByYear W23367040862013 @default.
• W2336704086 countsByYear W23367040862014 @default.
• W2336704086 countsByYear W23367040862015 @default.
• W2336704086 countsByYear W23367040862016 @default.
• W2336704086 countsByYear W23367040862017 @default.
• W2336704086 countsByYear W23367040862018 @default.
• W2336704086 countsByYear W23367040862019 @default.
• W2336704086 countsByYear W23367040862020 @default.
• W2336704086 countsByYear W23367040862021 @default.
• W2336704086 countsByYear W23367040862022 @default.
• W2336704086 countsByYear W23367040862023 @default.
• W2336704086 crossrefType "journal-article" @default.
• W2336704086 hasAuthorship W2336704086A5057744684 @default.
• W2336704086 hasAuthorship W2336704086A5075409072 @default.
• W2336704086 hasAuthorship W2336704086A5084967276 @default.
• W2336704086 hasAuthorship W2336704086A5088332392 @default.
• W2336704086 hasConcept C104317684 @default.
• W2336704086 hasConcept C109650736 @default.
• W2336704086 hasConcept C153911025 @default.
• W2336704086 hasConcept C181199279 @default.
• W2336704086 hasConcept C185592680 @default.
• W2336704086 hasConcept C187882448 @default.
• W2336704086 hasConcept C50605568 @default.
• W2336704086 hasConcept C526171541 @default.
• W2336704086 hasConcept C55493867 @default.
• W2336704086 hasConcept C86803240 @default.
• W2336704086 hasConcept C87644729 @default.
• W2336704086 hasConceptScore W2336704086C104317684 @default.
• W2336704086 hasConceptScore W2336704086C109650736 @default.
• W2336704086 hasConceptScore W2336704086C153911025 @default.
• W2336704086 hasConceptScore W2336704086C181199279 @default.
• W2336704086 hasConceptScore W2336704086C185592680 @default.
• W2336704086 hasConceptScore W2336704086C187882448 @default.
• W2336704086 hasConceptScore W2336704086C50605568 @default.
• W2336704086 hasConceptScore W2336704086C526171541 @default.
• W2336704086 hasConceptScore W2336704086C55493867 @default.
• W2336704086 hasConceptScore W2336704086C86803240 @default.

• next